Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 15 04:00PM ET
4.61
Dollar change
+0.13
Percentage change
2.90
%
IndexRUT P/E- EPS (ttm)-0.63 Insider Own19.55% Shs Outstand116.86M Perf Week17.60%
Market Cap539.97M Forward P/E- EPS next Y-0.41 Insider Trans1.96% Shs Float94.22M Perf Month4.77%
Income-63.48M PEG- EPS next Q-0.17 Inst Own59.00% Short Float6.68% Perf Quarter-8.71%
Sales21.05M P/S25.65 EPS this Y-23.77% Inst Trans0.72% Short Ratio9.42 Perf Half Y-27.29%
Book/sh2.57 P/B1.80 EPS next Y35.05% ROA-16.58% Short Interest6.29M Perf Year-7.43%
Cash/sh0.59 P/C7.82 EPS next 5Y- ROE-19.77% 52W Range3.56 - 6.72 Perf YTD-25.28%
Dividend Est.- P/FCF- EPS past 5Y- ROI-19.66% 52W High-31.35% Beta-0.04
Dividend TTM- Quick Ratio4.38 Sales past 5Y13.92% Gross Margin6.93% 52W Low29.49% ATR (14)0.21
Dividend Ex-Date- Current Ratio4.38 EPS Y/Y TTM-384.71% Oper. Margin-395.91% RSI (14)66.00 Volatility5.65% 5.02%
Employees106 Debt/Eq0.08 Sales Y/Y TTM-59.73% Profit Margin-301.63% Recom1.00 Target Price9.88
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-206.02% Payout- Rel Volume1.34 Prev Close4.48
Sales Surprise-35.24% EPS Surprise-17.79% Sales Q/Q-77.53% EarningsMay 09 AMC Avg Volume667.92K Price4.61
SMA2015.26% SMA507.52% SMA200-8.26% Trades Volume896,610 Change2.90%
Date Action Analyst Rating Change Price Target Change
Nov-29-23Initiated RBC Capital Mkts Outperform $6
Apr-21-23Initiated The Benchmark Company Buy $8
Apr-13-23Initiated Craig Hallum Buy $10
Feb-22-23Initiated Cowen Outperform $10
Feb-13-23Initiated H.C. Wainwright Buy $11
Dec-20-22Initiated Truist Buy $10
Dec-16-22Initiated Credit Suisse Outperform $13
Nov-29-22Initiated SVB Leerink Outperform $6
Nov-28-22Initiated Stifel Buy $12
Jun-03-24 04:05PM
May-20-24 08:05AM
May-15-24 04:05PM
May-12-24 03:24PM
May-09-24 08:56PM
04:05PM Loading…
04:05PM
May-01-24 08:00AM
Apr-22-24 08:00AM
Mar-21-24 11:31AM
Mar-20-24 08:54PM
04:05PM
Feb-28-24 08:27AM
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Dec-14-23 04:30PM
12:39PM Loading…
Nov-20-23 12:39PM
Nov-14-23 05:03AM
Nov-09-23 05:55PM
09:24AM
08:00AM
Nov-02-23 08:00AM
Nov-01-23 09:00AM
Oct-31-23 04:28PM
Oct-26-23 02:32PM
Oct-12-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:20AM
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
08:00AM Loading…
Jul-31-23 08:00AM
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
May-14-23 08:03AM
May-11-23 10:55PM
07:00AM
May-05-23 07:14AM
May-04-23 06:26AM
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
Mar-31-23 08:40AM
Mar-30-23 04:05PM
Mar-15-23 11:44AM
Mar-09-23 08:00AM
Mar-08-23 09:53AM
Feb-23-23 07:49AM
Feb-07-23 08:00AM
Feb-01-23 06:56AM
Dec-16-22 12:39PM
Dec-01-22 08:47AM
Nov-15-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:01PM
04:01PM
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Avista Capital Managing Member10% OwnerJun 29 '24Option Exercise3.3566,668223,33815,992,372Jul 02 05:00 PM
FOEHR MATTHEW WPresident and CEOJun 27 '24Option Exercise3.7359,659222,4163,599,166Jun 27 04:55 PM
FOEHR MATTHEW WPresident and CEOMay 24 '24Buy4.42240,0001,059,8403,536,665May 28 05:55 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOApr 08 '24Sale5.276,95436,648176,697Apr 09 06:38 PM
Berkman Charles SChief Legal OfficerApr 08 '24Sale5.276,95436,648292,617Apr 09 06:37 PM
GUSTAFSON KURT AExecutive VP, Finance & CFOApr 01 '24Sale5.4611,84964,696170,110Apr 02 06:30 PM
FOEHR MATTHEW WPresident and CEOMar 27 '24Option Exercise3.72243,613907,0233,152,416Mar 29 04:52 PM
FOEHR MATTHEW WPresident and CEOMar 22 '24Buy5.19225,0001,167,7502,908,803Mar 25 07:07 AM
FOEHR MATTHEW WChief Executive OfficerDec 12 '23Buy5.05200,0001,010,0002,645,442Dec 13 03:25 PM
FOEHR MATTHEW WPresident and CEONov 10 '23Buy4.2795,000405,5172,427,919Nov 13 08:00 AM
FOEHR MATTHEW WPresident and CEOAug 14 '23Buy5.4845,000246,6002,332,919Aug 15 04:56 PM
Last Close
Jul 15 04:00PM ET
96.67
Dollar change
-2.74
Percentage change
-2.76
%
LGND Ligand Pharmaceuticals, Inc. daily Stock Chart
IndexRUT P/E18.17 EPS (ttm)5.32 Insider Own2.54% Shs Outstand17.56M Perf Week11.27%
Market Cap1.74B Forward P/E16.42 EPS next Y5.89 Insider Trans-8.77% Shs Float17.51M Perf Month20.61%
Income96.34M PEG0.91 EPS next Q0.98 Inst Own93.27% Short Float5.34% Perf Quarter18.82%
Sales118.31M P/S14.67 EPS this Y-22.29% Inst Trans-0.32% Short Ratio6.48 Perf Half Y33.91%
Book/sh45.00 P/B2.15 EPS next Y24.39% ROA11.17% Short Interest0.93M Perf Year41.19%
Cash/sh17.29 P/C5.59 EPS next 5Y20.00% ROE13.26% 52W Range49.24 - 100.69 Perf YTD35.35%
Dividend Est.- P/FCF53.99 EPS past 5Y-13.18% ROI11.87% 52W High-3.99% Beta1.05
Dividend TTM- Quick Ratio19.51 Sales past 5Y-3.89% Gross Margin64.12% 52W Low96.32% ATR (14)3.50
Dividend Ex-DateJul 02, 2010 Current Ratio20.70 EPS Y/Y TTM290.26% Oper. Margin-1.18% RSI (14)69.88 Volatility4.80% 3.68%
Employees58 Debt/Eq0.01 Sales Y/Y TTM-45.70% Profit Margin81.43% Recom1.20 Target Price117.80
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q103.66% Payout0.00% Rel Volume0.99 Prev Close99.41
Sales Surprise10.94% EPS Surprise43.88% Sales Q/Q-29.56% EarningsMay 07 AMC Avg Volume144.29K Price96.67
SMA2014.13% SMA5016.03% SMA20035.39% Trades Volume142,859 Change-2.76%
Date Action Analyst Rating Change Price Target Change
Apr-14-21Resumed Stephens Overweight $200
Feb-04-21Reiterated H.C. Wainwright Buy $229 → $310
Oct-06-20Initiated Barclays Overweight $156
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
Jul-08-24 07:00AM
Jul-01-24 08:00AM
Jun-27-24 08:00AM
Jun-18-24 08:00AM
Jun-14-24 12:00PM
11:31AM Loading…
Jun-06-24 11:31AM
Jun-04-24 09:55AM
08:50AM
May-23-24 04:59PM
May-20-24 06:00AM
May-13-24 12:00PM
May-10-24 08:50AM
May-09-24 09:40AM
May-08-24 01:22PM
12:19PM
09:01PM Loading…
May-07-24 09:01PM
05:40PM
04:00PM
11:29AM
07:30AM
Apr-23-24 08:31AM
Apr-17-24 09:55AM
Apr-08-24 08:15AM
Apr-05-24 06:00PM
Apr-04-24 09:30AM
09:00AM
Apr-03-24 09:00AM
Apr-01-24 06:15PM
Mar-28-24 11:30AM
Mar-26-24 06:15PM
09:00AM Loading…
Mar-21-24 09:00AM
Mar-20-24 06:00PM
Mar-19-24 09:30AM
Mar-14-24 06:00PM
Mar-07-24 09:00AM
Mar-05-24 04:01PM
Mar-04-24 08:00AM
Feb-29-24 09:30AM
Feb-28-24 07:34AM
Feb-27-24 07:00AM
Feb-22-24 04:01PM
Feb-16-24 08:00AM
Feb-13-24 04:01PM
Feb-01-24 05:00PM
Jan-10-24 07:30PM
Jan-05-24 04:30PM
Dec-12-23 12:01PM
09:00AM
09:00AM
Dec-11-23 09:00AM
Dec-06-23 04:02PM
Dec-01-23 08:20AM
Nov-28-23 09:01AM
Nov-09-23 04:47PM
Nov-08-23 04:01PM
Nov-06-23 09:00AM
Nov-01-23 08:00AM
Oct-25-23 04:01PM
Oct-18-23 08:00AM
Oct-09-23 06:15PM
Oct-03-23 06:00PM
Oct-02-23 09:00AM
09:00AM
Sep-27-23 09:00AM
Sep-26-23 05:05PM
Sep-22-23 09:00AM
Sep-21-23 09:20AM
Sep-18-23 05:17PM
Sep-01-23 10:02PM
Aug-08-23 04:01PM
Jul-27-23 01:30PM
Jul-25-23 04:30PM
Jul-17-23 08:59AM
08:45AM
Jun-29-23 09:00AM
Jun-21-23 08:00PM
Jun-09-23 09:40AM
Jun-06-23 11:40AM
11:10AM
Jun-05-23 11:49AM
09:01AM
Jun-02-23 12:39PM
12:35PM
Jun-01-23 11:29AM
May-30-23 07:01PM
May-25-23 05:00PM
May-24-23 09:55AM
09:40AM
May-17-23 01:59PM
08:07AM
May-16-23 09:56AM
07:30AM
07:00AM
May-12-23 12:08PM
11:34AM
May-11-23 12:25PM
May-08-23 12:32PM
09:55AM
May-06-23 10:13AM
May-05-23 10:00AM
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Espinoza OctavioChief Financial OfficerMay 17 '24Option Exercise55.716,917385,34628,535May 17 07:59 PM
Espinoza OctavioChief Financial OfficerMay 17 '24Sale86.665,156446,84423,379May 17 07:59 PM
Espinoza OctavioChief Financial OfficerMay 16 '24Sale86.002,264194,71221,618May 17 07:59 PM
Espinoza OctavioChief Financial OfficerMay 15 '24Sale86.015,873505,14823,882May 17 07:59 PM
Korenberg Matthew EPresident & Chief OperatingMay 14 '24Sale85.1014,1581,204,91286,263May 15 07:34 PM
Korenberg Matthew EPresident & Chief OperatingMay 13 '24Sale84.543,440290,828100,421May 15 07:34 PM
Reardon AndrewChief Legal Officer &May 09 '24Option Exercise52.2710,000522,70032,205May 13 05:32 PM
Reardon AndrewChief Legal Officer &May 09 '24Sale83.0410,000830,44922,205May 13 05:32 PM
Gray Nancy RyanDirectorMay 09 '24Sale83.2093477,7135,633May 17 08:00 PM
Aryeh JasonDirectorApr 30 '24Option Exercise52.302,406125,83476,828May 02 06:07 PM
KOZARICH JOHN WDirectorApr 24 '24Option Exercise39.352,893113,84042,523Apr 26 06:35 PM
Davis Todd CChief Executive OfficerMar 25 '24Option Exercise57.3916,015919,147120,160Mar 27 05:47 PM
Aryeh JasonDirectorMar 05 '24Option Exercise39.352,893113,84074,422Mar 06 05:28 PM
Sabba Stephen LDirectorMar 05 '24Option Exercise0.002,893030,819Mar 07 01:27 PM
Sabba Stephen LDirectorMar 05 '24Sale74.301,893140,65028,926Mar 07 01:27 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Option Exercise56.621,26471,56429,895Feb 29 06:50 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Sale88.4614012,38429,755Feb 29 06:50 PM
Davis Todd CCHIEF EXECUTIVE OFFICERSep 22 '23Buy59.384,000237,52973,090Sep 25 04:44 PM
Last Close
Jul 15 04:00PM ET
77.21
Dollar change
-0.10
Percentage change
-0.13
%
TECH Bio-Techne Corp daily Stock Chart
IndexS&P 500 P/E61.37 EPS (ttm)1.26 Insider Own1.03% Shs Outstand157.64M Perf Week7.90%
Market Cap12.17B Forward P/E38.13 EPS next Y2.02 Insider Trans-0.88% Shs Float155.96M Perf Month-0.31%
Income202.97M PEG11.04 EPS next Q0.50 Inst Own101.71% Short Float3.22% Perf Quarter15.71%
Sales1.15B P/S10.54 EPS this Y-10.53% Inst Trans1.97% Short Ratio4.51 Perf Half Y5.56%
Book/sh12.79 P/B6.04 EPS next Y13.72% ROA7.63% Short Interest5.02M Perf Year-8.56%
Cash/sh0.92 P/C83.73 EPS next 5Y5.56% ROE10.40% 52W Range51.79 - 89.91 Perf YTD0.06%
Dividend Est.0.25 (0.33%) P/FCF48.45 EPS past 5Y16.30% ROI8.13% 52W High-14.13% Beta1.29
Dividend TTM0.32 (0.41%) Quick Ratio2.88 Sales past 5Y12.76% Gross Margin66.96% 52W Low49.08% ATR (14)1.95
Dividend Ex-DateMay 10, 2024 Current Ratio4.08 EPS Y/Y TTM-25.45% Oper. Margin21.92% RSI (14)63.12 Volatility2.89% 2.44%
Employees3050 Debt/Eq0.25 Sales Y/Y TTM2.73% Profit Margin17.58% Recom1.81 Target Price84.47
Option/ShortYes / Yes LT Debt/Eq0.24 EPS Q/Q-29.65% Payout18.16% Rel Volume0.64 Prev Close77.31
Sales Surprise3.86% EPS Surprise6.01% Sales Q/Q3.16% EarningsMay 01 BMO Avg Volume1.11M Price77.21
SMA205.21% SMA500.40% SMA2009.70% Trades Volume710,891 Change-0.13%
Date Action Analyst Rating Change Price Target Change
May-22-24Downgrade Citigroup Buy → Neutral $85
Feb-08-24Initiated Scotiabank Sector Outperform $80
Feb-02-24Downgrade Stifel Buy → Hold $65
Dec-07-23Initiated UBS Buy $80
Aug-28-23Initiated William Blair Outperform
Jan-10-23Upgrade Wells Fargo Underweight → Equal Weight $90
Dec-14-22Initiated Deutsche Bank Buy $100
Dec-12-22Upgrade Citigroup Neutral → Buy $81.25 → $100
Dec-07-22Initiated RBC Capital Mkts Sector Perform $89
Aug-25-22Initiated Credit Suisse Outperform $465
Today 07:00AM
Jul-12-24 06:58PM
Jul-09-24 06:00AM
Jul-02-24 07:06PM
May-31-24 07:00AM
07:00AM Loading…
May-30-24 07:00AM
May-29-24 07:00AM
May-23-24 10:26AM
07:00AM
May-22-24 07:00AM
May-20-24 01:34PM
May-14-24 04:49AM
May-08-24 07:00AM
May-07-24 07:00AM
May-06-24 05:57AM
11:40AM Loading…
May-02-24 11:40AM
11:31AM
10:49AM
10:34AM
08:17AM
08:00AM
03:11AM
May-01-24 04:54PM
02:05PM
01:52PM
12:08PM
11:10AM
09:30AM
08:36AM
07:51AM
07:40AM Loading…
07:40AM
07:29AM
06:30AM
06:30AM
Apr-30-24 07:00AM
Apr-29-24 10:38AM
09:39AM
07:00AM
Apr-26-24 07:00AM
Apr-24-24 10:01AM
Apr-23-24 07:00AM
Apr-10-24 07:00AM
Apr-08-24 07:00AM
Apr-03-24 07:00AM
Apr-01-24 07:00AM
Mar-28-24 09:00AM
08:39AM
Mar-22-24 07:00AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-12-24 07:00AM
Mar-11-24 07:00PM
Mar-06-24 07:00AM
Feb-23-24 06:15AM
Feb-13-24 08:00AM
Feb-02-24 10:47AM
04:45AM
Feb-01-24 12:57PM
07:51AM
07:07AM
06:30AM
06:30AM
Jan-29-24 07:00AM
Jan-25-24 07:00AM
Jan-24-24 07:00AM
Jan-21-24 01:16PM
Jan-16-24 07:00AM
Jan-05-24 07:00AM
Jan-04-24 07:00AM
Dec-21-23 07:00AM
Dec-20-23 07:00AM
Dec-14-23 07:00AM
Dec-01-23 01:32AM
Nov-27-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 07:00AM
Nov-01-23 10:44AM
Oct-31-23 07:53AM
07:27AM
06:30AM
06:30AM
Oct-25-23 03:42PM
09:00AM
Oct-22-23 10:30AM
Oct-20-23 05:01AM
Oct-19-23 07:00AM
Oct-16-23 07:00AM
Oct-10-23 07:00AM
Oct-03-23 09:45AM
Sep-28-23 06:00AM
Sep-27-23 07:00AM
Sep-26-23 07:00AM
Sep-25-23 07:00AM
Sep-23-23 09:00AM
Sep-19-23 02:00AM
Sep-18-23 07:32PM
10:14AM
Sep-08-23 11:35AM
Sep-06-23 12:04PM
Aug-28-23 07:32PM
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HIGGINS JOHN LDirectorJul 08 '24Option Exercise22.956,000137,70042,608Jul 10 04:35 PM
HIGGINS JOHN LDirectorMay 14 '24Option Exercise22.954,00091,80040,608May 16 04:17 PM
HIGGINS JOHN LDirectorMay 14 '24Sale83.844,000335,37736,608May 16 04:17 PM
Nusse RoelandDirectorMar 07 '24Sale76.9810,400800,62743,097Mar 11 04:04 PM
Hippel JamesCFODec 19 '23Option Exercise31.2647,2891,478,254104,850Dec 21 04:06 PM
Nusse RoelandDirectorAug 30 '23Option Exercise22.4032,000716,80060,811Sep 01 04:06 PM
Nusse RoelandDirectorAug 30 '23Sale80.328,939717,95951,872Sep 01 04:06 PM
Kelderman KimPres. Diagnostics & GenomAug 24 '23Option Exercise47.602,10099,96021,225Aug 28 04:19 PM
Kummeth Charles R.Chief Executive OfficerAug 15 '23Option Exercise0.0017,63201,286,944Aug 17 04:14 PM
Kummeth Charles R.Chief Executive OfficerAug 05 '23Option Exercise0.0051,51601,310,282Aug 08 05:31 PM
Hippel JamesCFOAug 05 '23Option Exercise0.0012,876063,896Aug 08 05:29 PM
Kelderman KimPres. Diagnostics & GenomAug 05 '23Option Exercise0.008,060023,264Aug 08 05:28 PM
Kummeth Charles R.Chief Executive OfficerJul 21 '23Sale88.3680,0007,069,0241,258,766Jul 25 05:27 PM